(ABT) Abbott Laboratories - Ratings and Ratios
Pharmaceuticals, Diagnostics, Nutrition, Devices, Generic
ABT EPS (Earnings per Share)
ABT Revenue
| Risk via 10d forecast | |
|---|---|
| Volatility | 18.9% |
| Value at Risk 5%th | 30.2% |
| Relative Tail Risk | -5.88% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.57 |
| Alpha | 7.78 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.416 |
| Beta | 0.236 |
| Beta Downside | 0.438 |
| Drawdowns 3y | |
|---|---|
| Max DD | 20.88% |
| Mean DD | 6.59% |
| Median DD | 5.46% |
Description: ABT Abbott Laboratories September 24, 2025
Abbott Laboratories (NYSE: ABT) operates globally across four core segments-Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices-leveraging a diversified portfolio that spans generic drugs, vaccines, point-of-care diagnostics, infant nutrition, cardiovascular implants, diabetes monitoring, and neuromodulation therapies.
The pharmaceutical arm supplies generics for a wide array of conditions (e.g., pancreatic exocrine insufficiency, dyslipidemia, hypertension, migraine) and specialty anti-infectives such as clarithromycin, while the diagnostics division offers immunoassay, clinical chemistry, hematology, molecular PCR platforms, rapid lateral-flow tests for pathogens (including SARS-CoV-2 and influenza), and cardiometabolic testing kits. The nutrition segment includes pediatric formulas and adult health supplements, and the medical-device business covers rhythm-management, heart-failure, vascular, structural-heart, diabetes-care, and chronic-pain neuromodulation devices.
Recent financial metrics (FY 2023) show revenue of $43.1 billion, a diluted EPS of $2.86, and free cash flow of roughly $6.5 billion, supporting a dividend yield near 1.5 % and a 2024-2025 share-repurchase plan of $5 billion. Abbott’s R&D spend averaged $3.2 billion (≈7.4 % of sales), reflecting its commitment to pipeline renewal in high-growth areas such as molecular diagnostics and cardiovascular devices. These figures are subject to macro-economic volatility, particularly currency fluctuations and US healthcare policy shifts, which could materially affect earnings.
Key sector drivers include an aging U.S. and global population that fuels demand for chronic-disease therapeutics, sustained growth in point-of-care testing accelerated by post-pandemic health-security concerns, and incremental pricing pressure from generic competition. Assuming continued reimbursement stability and no major supply-chain disruptions, Abbott’s diversified exposure positions it to capture a portion of the projected 5-6 % CAGR in global medical-device spend over the next five years.
For a deeper, data-driven valuation framework, the ValueRay platform provides granular scenario analysis that can help quantify Abbott’s upside and downside risks.
ABT Stock Overview
| Market Cap in USD | 219,724m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception | 1978-01-13 |
| Return 12m vs S&P 500 | 0.92% |
| Analyst Rating | 4.11 of 5 |
ABT Dividends
| Dividend Yield | 1.81% |
| Yield on Cost 5y | 2.27% |
| Yield CAGR 5y | 11.18% |
| Payout Consistency | 96.8% |
| Payout Ratio | 50.6% |
ABT Growth Ratios
| CAGR 3y | 10.15% |
| CAGR/Max DD Calmar Ratio | 0.49 |
| CAGR/Mean DD Pain Ratio | 1.54 |
| Current Volume | 5424.2k |
| Average Volume | 5293.9k |
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income (13.98b TTM) > 0 and > 6% of Revenue (6% = 2.63b TTM) |
| FCFTA 0.08 (>2.0%) and ΔFCFTA 0.72pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 21.67% (prev 21.59%; Δ 0.07pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.11 (>3.0%) and CFO 9.04b <= Net Income 13.98b (YES >=105%, WARN >=100%) |
| Net Debt (7.66b) to EBITDA (10.93b) ratio: 0.70 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.67 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (1.75b) change vs 12m ago 0.06% (target <= -2.0% for YES) |
| Gross Margin 53.98% (prev 50.98%; Δ 3.01pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 56.29% (prev 55.43%; Δ 0.86pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 14.11 (EBITDA TTM 10.93b / Interest Expense TTM 451.0m) >= 6 (WARN >= 3) |
Altman Z'' 5.23
| (A) 0.12 = (Total Current Assets 23.66b - Total Current Liabilities 14.16b) / Total Assets 81.41b |
| (B) 0.58 = Retained Earnings (Balance) 47.26b / Total Assets 81.41b |
| (C) 0.08 = EBIT TTM 6.37b / Avg Total Assets 77.89b |
| (D) 1.92 = Book Value of Equity 64.51b / Total Liabilities 33.51b |
| Total Rating: 5.23 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 72.66
| 1. Piotroski 6.0pt = 1.0 |
| 2. FCF Yield 2.98% = 1.49 |
| 3. FCF Margin 15.45% = 3.86 |
| 4. Debt/Equity 0.32 = 2.45 |
| 5. Debt/Ebitda 0.70 = 2.13 |
| 6. ROIC - WACC (= 1.22)% = 1.52 |
| 7. RoE 29.92% = 2.49 |
| 8. Rev. Trend 86.86% = 6.51 |
| 9. EPS Trend 23.93% = 1.20 |
What is the price of ABT shares?
Over the past week, the price has changed by +3.35%, over one month by -1.58%, over three months by +1.46% and over the past year by +15.68%.
Is Abbott Laboratories a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ABT is around 126.79 USD . This means that ABT is currently overvalued and has a potential downside of -2.91%.
Is ABT a buy, sell or hold?
- Strong Buy: 12
- Buy: 7
- Hold: 9
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ABT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 144.5 | 10.6% |
| Analysts Target Price | 144.5 | 10.6% |
| ValueRay Target Price | 138.8 | 6.3% |
ABT Fundamental Data Overview November 09, 2025
P/E Trailing = 15.8744
P/E Forward = 23.3645
P/S = 5.0116
P/B = 4.5775
P/EG = 4.1675
Beta = 0.719
Revenue TTM = 43.84b USD
EBIT TTM = 6.37b USD
EBITDA TTM = 10.93b USD
Long Term Debt = 12.62b USD (from longTermDebt, last fiscal year)
Short Term Debt = 1.75b USD (from shortTermDebt, last fiscal year)
Debt = 15.28b USD (from shortLongTermDebtTotal, last fiscal year)
Net Debt = 7.66b USD (from netDebt column, last fiscal year)
Enterprise Value = 227.38b USD (219.72b + Debt 15.28b - CCE 7.62b)
Interest Coverage Ratio = 14.11 (Ebit TTM 6.37b / Interest Expense TTM 451.0m)
FCF Yield = 2.98% (FCF TTM 6.78b / Enterprise Value 227.38b)
FCF Margin = 15.45% (FCF TTM 6.78b / Revenue TTM 43.84b)
Net Margin = 31.88% (Net Income TTM 13.98b / Revenue TTM 43.84b)
Gross Margin = 53.98% ((Revenue TTM 43.84b - Cost of Revenue TTM 20.18b) / Revenue TTM)
Gross Margin QoQ = 55.75% (prev 56.44%)
Tobins Q-Ratio = 2.79 (Enterprise Value 227.38b / Total Assets 81.41b)
Interest Expense / Debt = 0.29% (Interest Expense 44.0m / Debt 15.28b)
Taxrate = 24.59% (536.0m / 2.18b)
NOPAT = 4.80b (EBIT 6.37b * (1 - 24.59%))
Current Ratio = 1.67 (Total Current Assets 23.66b / Total Current Liabilities 14.16b)
Debt / Equity = 0.32 (Debt 15.28b / totalStockholderEquity, last fiscal year 47.66b)
Debt / EBITDA = 0.70 (Net Debt 7.66b / EBITDA 10.93b)
Debt / FCF = 1.13 (Net Debt 7.66b / FCF TTM 6.78b)
Total Stockholder Equity = 46.71b (last 4 quarters mean from totalStockholderEquity)
RoA = 17.17% (Net Income 13.98b / Total Assets 81.41b)
RoE = 29.92% (Net Income TTM 13.98b / Total Stockholder Equity 46.71b)
RoCE = 10.73% (EBIT 6.37b / Capital Employed (Equity 46.71b + L.T.Debt 12.62b))
RoIC = 7.67% (NOPAT 4.80b / Invested Capital 62.61b)
WACC = 6.45% (E(219.72b)/V(235.00b) * Re(6.88%) + D(15.28b)/V(235.00b) * Rd(0.29%) * (1-Tc(0.25)))
Discount Rate = 6.88% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 33.33 | Cagr: 0.03%
[DCF Debug] Terminal Value 77.16% ; FCFE base≈6.33b ; Y1≈5.88b ; Y5≈5.38b
Fair Price DCF = 55.50 (DCF Value 96.51b / Shares Outstanding 1.74b; 5y FCF grow -9.03% → 3.0% )
EPS Correlation: 23.93 | EPS CAGR: 8.83% | SUE: 0.0 | # QB: 0
Revenue Correlation: 86.86 | Revenue CAGR: 4.43% | SUE: -0.19 | # QB: 0
Additional Sources for ABT Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle